133 related articles for article (PubMed ID: 16249698)
1. Role of lymphocyte multidrug resistance protein 1 in HIV infection: expression, function, and consequences of inhibition.
Lucia MB; Savarino A; Straface E; Golotta C; Rastrelli E; Matarrese P; Rutella S; Malorni W; Cauda R
J Acquir Immune Defic Syndr; 2005 Nov; 40(3):257-66. PubMed ID: 16249698
[TBL] [Abstract][Full Text] [Related]
2. ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.
Jorajuria S; Dereuddre-Bosquet N; Becher F; Martin S; Porcheray F; Garrigues A; Mabondzo A; Benech H; Grassi J; Orlowski S; Dormont D; Clayette P
Antivir Ther; 2004 Aug; 9(4):519-28. PubMed ID: 15456083
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.
Janneh O; Jones E; Chandler B; Owen A; Khoo SH
J Antimicrob Chemother; 2007 Nov; 60(5):987-93. PubMed ID: 17890284
[TBL] [Abstract][Full Text] [Related]
4. Suppression of HIV-1 Viral Replication by Inhibiting Drug Efflux Transporters in Activated Macrophages.
Mu Y; Cory TJ
Curr HIV Res; 2021; 19(2):128-137. PubMed ID: 33032513
[TBL] [Abstract][Full Text] [Related]
5. Host factors and efficacy of antiretroviral treatment.
Turriziani O; Antonelli G
New Microbiol; 2004 Apr; 27(2 Suppl 1):63-9. PubMed ID: 15646066
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients.
De Milito A; Catucci M; Venturi G; Romano L; Incandela L; Valensin PE; Zazzi M
J Med Virol; 1999 Feb; 57(2):140-4. PubMed ID: 9892398
[TBL] [Abstract][Full Text] [Related]
7. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).
Olson DP; Scadden DT; D'Aquila RT; De Pasquale MP
AIDS; 2002 Sep; 16(13):1743-7. PubMed ID: 12218384
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy.
Raulin J
Prog Lipid Res; 2002 Jan; 41(1):27-65. PubMed ID: 11694268
[TBL] [Abstract][Full Text] [Related]
9. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.
Janneh O; Anwar T; Jungbauer C; Kopp S; Khoo SH; Back DJ; Chiba P
Antivir Ther; 2009; 14(7):965-74. PubMed ID: 19918100
[TBL] [Abstract][Full Text] [Related]
11. Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing.
O'Meara D; Wilbe K; Leitner T; Hejdeman B; Albert J; Lundeberg J
J Clin Microbiol; 2001 Feb; 39(2):464-73. PubMed ID: 11158091
[TBL] [Abstract][Full Text] [Related]
12. Anti-HIV effects of chloroquine: inhibition of viral particle glycosylation and synergism with protease inhibitors.
Savarino A; Lucia MB; Rastrelli E; Rutella S; Golotta C; Morra E; Tamburrini E; Perno CF; Boelaert JR; Sperber K; Cauda R
J Acquir Immune Defic Syndr; 2004 Mar; 35(3):223-32. PubMed ID: 15076236
[TBL] [Abstract][Full Text] [Related]
13. Cellular issues relating to the resistance of HIV to antiretroviral agents.
Turriziani O; Scagnolari C; Bellomi F; Solimeo I; Focher F; Antonelli G
Scand J Infect Dis Suppl; 2003; 106():45-8. PubMed ID: 15000583
[TBL] [Abstract][Full Text] [Related]
14. Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression.
Ford J; Meaden ER; Hoggard PG; Dalton M; Newton P; Williams I; Khoo SH; Back DJ
J Antimicrob Chemother; 2003 Sep; 52(3):354-8. PubMed ID: 12917239
[TBL] [Abstract][Full Text] [Related]
15. Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers.
Lee LS; Soon GH; Shen P; Yong EL; Flexner C; Pham P
Antivir Ther; 2010; 15(2):275-9. PubMed ID: 20386083
[TBL] [Abstract][Full Text] [Related]
16. Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein.
Bousquet L; Pruvost A; Didier N; Farinotti R; Mabondzo A
Eur J Pharm Sci; 2008 Nov; 35(4):247-56. PubMed ID: 18692133
[TBL] [Abstract][Full Text] [Related]
17. Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
Benito JM; López M; Martín JC; Lozano S; Martínez P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1379-88. PubMed ID: 12487809
[TBL] [Abstract][Full Text] [Related]
18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
19. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
[TBL] [Abstract][Full Text] [Related]
20. How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?
Garbelli A; Riva V; Crespan E; Maga G
Biochem J; 2017 Apr; 474(10):1559-1577. PubMed ID: 28446620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
